Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
McGill University
$120,000.00
Conversion of Gene Therapy into RNA Therapy Using a Novel Nanoparticle System
EF 2025-26
Résumé
Autosomal Recessive Spastic Ataxia of the Charlevoix-Saguenay (ARSACS) is a rare hereditary neurological disorder that impairs motor control functions. ARSACS is caused by mutations in the SACS gene, leading to the dysfunction of a giant protein enriched in the brain, known as sacsin. Given that ARSACS arises from mutations in a single gene, it is an ideal candidate for gene replacement therapy. However, sacsin is too large to be packaged into viral delivery systems (AAV vectors) that are commonly used for gene therapy. To overcome this challenge, our group designed a "minisacsin" protein that retains sacsin's key functions. In cellular and mouse models of ARSACS, delivery of minisacsin using AAV vectors corrected pathological abnormalities and prevented abnormal motor behaviour. However, the longer-term studies indicated that additional doses would be required, which is not feasible with AAV vectors due to their immunogenic properties. Hence, this project aims to transition from gene therapy to RNA-based approaches, which allow for adjustable and repeated dosing. Through collaboration with QurCan Therapeutics, we will utilize their novel nanoparticle system (C-TERP) that can deliver therapeutic RNA to nerve cells. The objectives of this project include 1) assessing the delivery and safety of minisacsin-RNA in cellular culture models; 2) comparing the effectiveness of the nanoparticles to deliver DNA and RNA compared to AAV-mediated delivery; and 3) treating symptomatic ARSACS mice and assessing motor behaviour. By developing a precise and effective therapy for ARSACS, this project can establish a model for testing RNA-based treatments applicable to other rare neurological disorders caused by single-gene mutations.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
560246
Name
Atkinson Caitlin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Conversion of Gene Therapy into RNA Therapy Using a Novel Nanoparticle System
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Arsacs; Ataxia; Cellular Biology; Gene Therapy; Nanoparticles; Neurological Disease; Rna Therapy
Abstract
Autosomal Recessive Spastic Ataxia of the Charlevoix-Saguenay (ARSACS) is a rare hereditary neurological disorder that impairs motor control functions. ARSACS is caused by mutations in the SACS gene, leading to the dysfunction of a giant protein enriched in the brain, known as sacsin. Given that ARSACS arises from mutations in a single gene, it is an ideal candidate for gene replacement therapy. However, sacsin is too large to be packaged into viral delivery systems (AAV vectors) that are commonly used for gene therapy. To overcome this challenge, our group designed a "minisacsin" protein that retains sacsin's key functions. In cellular and mouse models of ARSACS, delivery of minisacsin using AAV vectors corrected pathological abnormalities and prevented abnormal motor behaviour. However, the longer-term studies indicated that additional doses would be required, which is not feasible with AAV vectors due to their immunogenic properties. Hence, this project aims to transition from gene therapy to RNA-based approaches, which allow for adjustable and repeated dosing. Through collaboration with QurCan Therapeutics, we will utilize their novel nanoparticle system (C-TERP) that can deliver therapeutic RNA to nerve cells. The objectives of this project include 1) assessing the delivery and safety of minisacsin-RNA in cellular culture models; 2) comparing the effectiveness of the nanoparticles to deliver DNA and RNA compared to AAV-mediated delivery; and 3) treating symptomatic ARSACS mice and assessing motor behaviour. By developing a precise and effective therapy for ARSACS, this project can establish a model for testing RNA-based treatments applicable to other rare neurological disorders caused by single-gene mutations.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Atkinson, Caitlin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~